I take it everybody here has read the latest from the CEO on the Novogen website?
The last section titled "other developments " contains the following; Outside of CanTx, the effort to produce a related product for the treatment of glioblastoma is running in parallel, again using the most stringent model that we could come up with. We will talk about that program in the near future, but when we do, it won’t be because we have only stopped the growth of a commercial glioblastoma cell line under the skin of a mouse.
Sounds positive.
Based on recent market moves it probably won't have much effect on the shareprice but reading the entire post in conjunction with Dr. Kelly's' response to an email from '"Neg" is food for thought.
Why "cap" a shareprice? Can a shareprice be "capped" indefinitely?
I am still a buyer with a longer term view.
NRT Price at posting:
18.0¢ Sentiment: LT Buy Disclosure: Held